The Sepsis Marker “Presepsin”: Biochemistry and Clinical Diagnosis
Keywords:
Presepsin, Sepsis, Severity, CD14, Diagnostic markerAbstract
Presepsin (P-SEP), an approximately 70-amino-acid fragment of CD14, a lipopolysaccharide (LPS) receptor that transmits signals through CD14-MD-2/TLR4 to cells, was first discovered as a sepsis marker in 2002 when high concentrations of a protein with soluble CD14-like immunoreactivity were detected in the blood of sepsis patients. We used an immunoassay to measure the serum concentrations of the new peptide, which was initially named soluble CD14-subtype (sCD14-ST) and later renamed presepsin. Rabbit sepsis models revealed that presepsin is induced by the cecal ligation and punctual (CLP) sepsis model but not by the LPS injection model. In vitro experiments using human monocytes and neutrophils suggested that presepsin is produced when bacteria are phagocytosed by immune cells. The first clinical study was initiated by Professor Shigeatsu Endo (Iwate Medical University, Japan). It demonstrated that sepsis patients have higher presepsin levels compared with Systemic Inflammatory Response Syndrome (SIRS) patients, indicating that presepsin could be useful for sepsis diagnosis. This interesting marker is not only helpful for the diagnosis of sepsis but is also indicative of disease severity, as measured by the Sequential Organ Failure Assessment (SOFA) score. More researches are necessary as the understanding of the fundamental aspects of presepsin is still limited. Presepsin is elevated in high-mortality elective cardiac surgery and severe COVID-19 patients, but the mechanism by which presepsin production is increased during severe COVID-19 disease is unknown. In this article, presepsin biochemistry is described, then the application of presepsin in clinical diagnosis is discussed.
References
Arai Y, Mizugishi K, Nonomura K, et al., 2015, Phagocytosis by Human Monocytes is Required for the Secretion of Presepsin. J Infect Chemother, 2015(21): 564–569.
Kim JI, Lee CJ, Jin MS, et al., 2005, Crystal Structure of CD14 and Its Implications for Lipopolysaccharide Signaling. J Biol Chem, 2005(280): 11347–11351.
Juan TS, Kelley MJ, Johnson DA, et al., 1995, Soluble CD14 Truncated at Amino Acid 152 Binds Lipopolysaccharide (LPS) and Enables Cellular Response to LPS. Biol Chem, 1995(270): 1382–1387.
Giavarina D, Carta M, 2015, Determination of the Reference Interval for Presepsin, an Early Marker for Sepsis. Biochem Med (Zagreb), 2015(25): 64–68.
Ham JY, Song KE, 2016, Impact of Specimen Mixing Methods on Presepsin Point-Of-Care Test Results using Whole Blood. Clin Chem Lab Med, 2106(54): e151–154.
Sakamoto D, Oyamada T, Miyagi H, et al., Effect of Physical Shock from Air Shooter® Transport on Presepsin Values. Medical Testing and Automation (in submission).
Ebisawa K, Koya J, Nakazaki K, et al., 2018, Usefulness of Presepsin for Early Detection of Infections in Patients with Haematologic Disorders. Clin Chim Acta, 2018(486): 374–380.
Endo S, Azushima T, Takahashi M, et al., 2016, Characteristics and Usefulness of the Sepsis Biomarker “Presepsin.” Infectious Diseases, 2016(46): 10–15.
Takahashi M, Endo S, Shigekazu Endo, Tatsuyori Azushima, et al., 2016, “Preceptin”: What We Have Learned Through Cases. Department of Emergency and Disaster Medicine, Iwate Medical University School of Medicine, 10.
Takeuchi M, Yokose T, Kawakubo H, et al., 2020, The Perioperative Presepsin as an Accurate Diagnostic Marker of Postoperative Infectious Complications. After Esophagectomy: A Prospective Cohort Study. Esophagus, 2020(17): 399–407. http://doi.org/10.1007/s10388-020-00736-7
Yu H, Qi Z, Hang C, et al., 2017, Evaluating the Value of Dynamic Procalcitonin and Presepsin Measurements for Patients with Severe Sepsis. Am J Emerg Med, 2017(35): 835–841.
Fujii E, Fujino K, Eguchi Y, 2019, An Evaluation of Clinical Inflammatory and Coagulation Markers in Patients with Sepsis: A Pilot Study. Acute Med Surg, 2019(6): 158–164.
Klouche K, Cristol JP, Devin J, et al., 2016, Diagnostic and Prognostic Value of Soluble CD14 Subtype (Presepsin) for Sepsis and Community-Acquired Pneumonia in ICU Patients. Ann Intensive Care, 2016(6): 59.
Bamba Y, Moro H, Aoki N, et al., 2018, Increased Presepsin Levels are Associated with the Severity of Fungal Bloodstream Infections. PLoS One, 2018(13): e0206089.
Apiratwarakul K, Srimookda N, Phungoen P, et al., 2020, Presepsin Levels in Emergency Patients with Bacterial and Viral Infection. Open Access Maced J Med Sci, 2020(8): 20–23.
Tambo M, Taguchi S, Nakamura Y, et al., 2020, Presepsin and Procalcitonin as Predictors of Sepsis Based on the New Sepsis-3 Definitions. BMC Urol, 2020(20): 23.
Bomberg H, Klingele M, Wagenpfeil S, et al., 2017, Presepsin (sCD14-ST) is a Novel Marker for Risk Stratification in Cardiac Surgery Patients. Anesthesiology, 2017(126): 631–642.
Fukada A, Nakabefu N, Matsuoka M, et al., 2020, Usefulness of Presepsin in COVID-19. Infectious Diseases Society of Japan COVID-19 Case Report Collection.
